Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
This Week In Space podcast: Episode 189 — Privatizing Orbit - 2What Middle East Conflict Could Mean For The World’s Largest Whale Shark Gathering
- 3Higher cost, worse coverage: Affordable Care Act enrollees say expiring subsidies will hit them hard
- 42026 Golden Globes: How to watch, start time, TV channel, full nominee list and more
- 5Report in relation to renaming Herzog Park set to be withdrawn
- Lebanon’s Hezbollah and Yemen’s Houthis join Iran in strike on Israel
- 1st human missions to Mars should hunt for signs of life, report says
- The Response Uncovered: Disentangling the Secrets of the Universe
- Nordic people know how to beat the winter blues. Here's how to find light in the darkest months
- Freed whale gets stranded again off German coast
- How to track NASA’s Artemis II and Orion’s journey to the moon
- Iran plans new restrictions in overhaul of Strait of Hormuz rules
- Netanyahu vows to ‘return Negev to Israel,’ pledges settlement growth during visit
- Triumph's 400 Range Has Just Changed In India, And Here's Why
